New horizons in the treatment of multiple sclerosis.
OBJECTIVE
To review and discuss novel therapeutic approaches to multiple sclerosis (MS), particularly strategies designed to modulate immunopathogenetic mechanisms.


METHODS
Recent medical and scientific publications and the proceedings of recent conferences in Australia and the United States.


CONCLUSIONS
Clearer understanding of the pathogenetic mechanisms leading to inflammation and demyelination in MS is suggesting new strategies for intervention. Both antigen-specific and non-antigen-specific immunomodulation can be achieved in animal models, and human clinical trials of several new agents can be expected shortly.
Heard
R N
RN
Department of Neurology, Royal Prince Alfred Hospital, Camperdown, NSW.
D000906:Antibodies / Q000008:administration & dosage; D006801:Humans; D009103:Multiple Sclerosis / Q000276:immunology / Q000628:therapy*; D009186:Myelin Sheath / Q000502:physiology; D013601:T-Lymphocytes / Q000276:immunology
D000906:Antibodies